Challenges to curing primary brain tumours
Research output: Contribution to journal › Review article
Colleges, School and Institutes
- Department of Pathology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
- University of Cambridge
- Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, U.K.
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
- Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
- Telethon Kids Institute, University of Western Australia, Subiaco, Western Australia 6008, Australia.
- Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.
- Great Ormond Street Hospital for Children, London, UK.
- Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
- Pediatric Glioma Research Group, Hopp Children's Cancer Center at the NCT Heidelberg, Heidelberg, Germany.
- Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
- Human Oncology and Pathogenesis Program and Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Oncology, AstraZeneca IMED Biotech Unit, Boston, MA, USA.
- Division of Pediatric Oncology, Hopp Children's Cancer Center at the NCT Heidelberg, Heidelberg, Germany.
- Cancer Research UK Edinburgh Centre and Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.
- Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, CA, USA.
- The Preston Robert Tisch Brain Tumor Center, Duke Cancer Center, Durham, NC, USA.
- The Arthur and Sonia Labatt Brain Tumour Research Centre and Division of Neurosurgery, The Hospital for Sick Children, Toronto, Ontario, Canada.
Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour. The seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment.
|Number of pages||12|
|Journal||Nature Reviews Clinical Oncology|
|Early online date||7 Feb 2019|
|Publication status||E-pub ahead of print - 7 Feb 2019|